Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

VRDN Relative to the S&P 500

VRDN Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Viridian Therapeutics, Inc. (NASD:VRDN) seasonal charts above shows that a Buy Date of November 8 and a Sell Date of February 3 has resulted in a geometric average return of 19.18% above the benchmark rate of the S&P 500 Total Return Index over the past 10 years. This seasonal timeframe has shown positive results compared to the benchmark in 7 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 10 years by an average of 55.96% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

To download VRDN seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: VRDN